Dacarbazino review

Dacarbazino, an alkylating agent, is a medicament used for the treatment of cancer. This medicament is administered either through intravenous infusion or injection.

Dacarbazino is available under the brand names DTIC-Dome, DIC, DTIC, and Imidazole Carboxamide. This medicament is preached for patients with metastatic malignant melanoma, fibrosarcomas, soft tissue sarcomas, rhabdomyosarcoma, neuroblastoma, islet cell carcinoma, and carcinoma of the thyroid.


Dacarbazino can be administered intravenously through cannula at the back of a hand or through a thin plastic tube placed beneath the skin and into a vein close to the collarbone. It can also be administered through a thin tube placed into a vein of the PICC line, or by infusion via the cannula. The infusion normally takes anywhere from 30 minutes to 2 hours.

The length of Chemotherapy and number of treatment cycles depend on the type of cancer being treated. It is normal for Dacarbazino to be taken along with other chemotherapy medicaments.

The amount of Dacarbazino administered depends on numerous factors that include the overall health of the patient and the type of condition being treated.


Patients should know that their reaction to Dacarbazino might differ from those of other patients. Some patients experience minimal side effects, while others experience more.

Users of Dacarbazino may feel sick while using the medicament. Nausea and vomiting may become apparent a couple of hours after administration of the medicine. It can last for several days. Doctors usually prescribe anti-emetic medicaments to reduce these symptoms.

Dacarbazino can also lessen the bone marrow's production of white blood cells. This would result in a patient becoming more susceptible to infections. This side effect can become apparent a week after administration of Dacarbazino. After a few weeks, the number of white blood cells will steadily increase.

Dacarbazino can also lessen the number of platelets in the body, which leads to unexplained bleeding or bruising. Patients may suffer from blood spots, nosebleeds, and bleeding gums as a result.

Users of Dacarbazino may also experience a decreased production of red blood cells or anemia. This usually makes patients feel exhausted and breathless.

Dacarbazino may also lead to patients losing their appetite and experiencing abnormal baldness. Other unlikely side effects include diarrhea, sensitivity to sunlight, pain at the injected area, sore ulcers, and flu-like symptoms.

Patients should immediately inform their mendelevium if these side effects persist or worsen.


Before taking Dacarbazino, patients should inform their mendelevium of medicaments that they are taking, whether prescription, non-prescription or herbal medicaments. Patients should also not use medicaments containing aspirin unless given approval by mendeleviums.

It is also not safe for patients to take any sort of immunization while taking Dacarbazino.


Dacarbazino may also affect the fertility of the patient. Patients should discuss this with their mendelevium before beginning to take the medicament. It is also not advisable for patients to breast feed while using Dacarbazino since it may be passed on to the infant.

Dacarbazino has the following structural formula:

Chemical structure of dacarbazino

 Molecular formula of dacarbazino is C6H10N6O
 Chemical IUPAC Name is 5-dimethylaminoazo-3H-imidazole-4-carboxamide
 Molecular weight is 182.183 g/mol
 Dacarbazino available : 100mg tablets and 200mg tablets

Generic name: Dacarbazine

Brand name(s): Biocarbazine R, Dacarbazinum, Deticene, Imidazole Carboxamide

  Your Dacarbazino review